Douglas B Muchmore

Summary

Publications

  1. pmc Accelerating and improving the consistency of rapid-acting analog insulin absorption and action for both subcutaneous injection and continuous subcutaneous infusion using recombinant human hyaluronidase
    Douglas B Muchmore
    Halozyme Therapeutics Inc, San Diego, California 92121, USA
    J Diabetes Sci Technol 6:764-72. 2012
  2. pmc The end point is just the beginning
    Douglas Muchmore
    Halozyme Therapeutics, Inc, San Diego, California 92121, USA
    J Diabetes Sci Technol 5:1287-9. 2011
  3. pmc Benefits of blinded continuous glucose monitoring during a randomized clinical trial
    Douglas Muchmore
    Halozyme Therapeutics, Inc, San Diego, California, USA
    J Diabetes Sci Technol 5:676-80. 2011
  4. pmc Review of the mechanism of action and clinical efficacy of recombinant human hyaluronidase coadministration with current prandial insulin formulations
    Douglas B Muchmore
    Halozyme Therapeutics, Inc, San Diego, California, USA
    J Diabetes Sci Technol 4:419-28. 2010
  5. doi request reprint Use of recombinant human hyaluronidase to accelerate rapid insulin analogue absorption: experience with subcutaneous injection and continuous infusion
    Daniel E Vaughn
    Halozyme Therapeutics, Inc, San Diego, California 92121, USA
    Endocr Pract 17:914-21. 2011
  6. doi request reprint Reduction in intrasubject variability in the pharmacokinetic response to insulin after subcutaneous co-administration with recombinant human hyaluronidase in healthy volunteers
    Linda Morrow
    Profil Institute for Clinical Research, Chula Vista, California, USA
    Diabetes Technol Ther 13:1039-45. 2011
  7. doi request reprint Improved postprandial glycemic control in patients with type 2 diabetes from subcutaneous injection of insulin lispro with hyaluronidase
    Marcus Hompesch
    Profil Institute for Clinical Research, Chula Vista, California, USA
    Diabetes Technol Ther 14:218-24. 2012
  8. doi request reprint Accelerated pharmacokinetics and glucodynamics of prandial insulins injected with recombinant human hyaluronidase
    Daniel E Vaughn
    Halozyme Therapeutics, Inc, San Diego, California 92121, USA
    Diabetes Technol Ther 11:345-52. 2009
  9. pmc Accelerated insulin pharmacokinetics and improved postprandial glycemic control in patients with type 1 diabetes after coadministration of prandial insulins with hyaluronidase
    Marcus Hompesch
    Profil Institute for Clinical Research, Chula Vista, California, USA
    Diabetes Care 34:666-8. 2011
  10. pmc Inhaled insulin for controlling blood glucose in patients with diabetes
    Bernard L Silverman
    Alkermes, Inc, Cambridge, MA, USA
    Vasc Health Risk Manag 3:947-58. 2007

Collaborators

Detail Information

Publications10

  1. pmc Accelerating and improving the consistency of rapid-acting analog insulin absorption and action for both subcutaneous injection and continuous subcutaneous infusion using recombinant human hyaluronidase
    Douglas B Muchmore
    Halozyme Therapeutics Inc, San Diego, California 92121, USA
    J Diabetes Sci Technol 6:764-72. 2012
    ..Further studies of rHuPH20 in the take-home treatment setting are underway...
  2. pmc The end point is just the beginning
    Douglas Muchmore
    Halozyme Therapeutics, Inc, San Diego, California 92121, USA
    J Diabetes Sci Technol 5:1287-9. 2011
    ..An example would be "percentage of patients achieving A1C <7% without unacceptable hypoglycemia." The benefits and limitations of such an approach are discussed...
  3. pmc Benefits of blinded continuous glucose monitoring during a randomized clinical trial
    Douglas Muchmore
    Halozyme Therapeutics, Inc, San Diego, California, USA
    J Diabetes Sci Technol 5:676-80. 2011
    ..This study was designed to investigate the use of novel procedures to enhance data capture from blinded CGM...
  4. pmc Review of the mechanism of action and clinical efficacy of recombinant human hyaluronidase coadministration with current prandial insulin formulations
    Douglas B Muchmore
    Halozyme Therapeutics, Inc, San Diego, California, USA
    J Diabetes Sci Technol 4:419-28. 2010
    ....
  5. doi request reprint Use of recombinant human hyaluronidase to accelerate rapid insulin analogue absorption: experience with subcutaneous injection and continuous infusion
    Daniel E Vaughn
    Halozyme Therapeutics, Inc, San Diego, California 92121, USA
    Endocr Pract 17:914-21. 2011
    ..To discuss clinical studies in which recombinant human hyaluronidase (rHuPH20) was used to increase insulin dispersion and accelerate its absorption...
  6. doi request reprint Reduction in intrasubject variability in the pharmacokinetic response to insulin after subcutaneous co-administration with recombinant human hyaluronidase in healthy volunteers
    Linda Morrow
    Profil Institute for Clinical Research, Chula Vista, California, USA
    Diabetes Technol Ther 13:1039-45. 2011
    ....
  7. doi request reprint Improved postprandial glycemic control in patients with type 2 diabetes from subcutaneous injection of insulin lispro with hyaluronidase
    Marcus Hompesch
    Profil Institute for Clinical Research, Chula Vista, California, USA
    Diabetes Technol Ther 14:218-24. 2012
    ....
  8. doi request reprint Accelerated pharmacokinetics and glucodynamics of prandial insulins injected with recombinant human hyaluronidase
    Daniel E Vaughn
    Halozyme Therapeutics, Inc, San Diego, California 92121, USA
    Diabetes Technol Ther 11:345-52. 2009
    ..Indianapolis, IN) or regular human insulin (Humulin R; Eli Lilly and Co.) administered with or without (+/-) recombinant human hyaluronidase (rHuPH20)...
  9. pmc Accelerated insulin pharmacokinetics and improved postprandial glycemic control in patients with type 1 diabetes after coadministration of prandial insulins with hyaluronidase
    Marcus Hompesch
    Profil Institute for Clinical Research, Chula Vista, California, USA
    Diabetes Care 34:666-8. 2011
    ..To compare the pharmacokinetics, pharmacodynamics, and safety of insulin lispro or regular human insulin (RHI) with or without recombinant human hyaluronidase (rHuPH20) administered before a standardized meal...
  10. pmc Inhaled insulin for controlling blood glucose in patients with diabetes
    Bernard L Silverman
    Alkermes, Inc, Cambridge, MA, USA
    Vasc Health Risk Manag 3:947-58. 2007
    ....